Robert Fogel, MD

Vice President, Global Medical Affairs, Respiratory & Immunology, AstraZeneca
BioPharmaceuticals R&D, AstraZeneca

Poster(s):

• (407) As-needed albuterol–budesonide decreases risk of severe asthma exacerbation in the first three months post-randomization compared to albuterol in patients treated for moderate-to-severe asthma: MANDALA post-hoc analysis
  Wednesday, October 29, 2025